Core Viewpoint - The company, 加科思-B (01167), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 138,000 shares at a total cost of HKD 981,400 [1] - The buyback price per share ranges from HKD 7.08 to HKD 7.16 [1] - The buyback is scheduled for October 24, 2025 [1]

Core Viewpoint - 加科思-B (01167.HK) announced a share buyback of 138,000 shares at a cost of HKD 981,000 on October 24 [1] Group 1 - The company executed a buyback program on October 24 [1] - The total expenditure for the buyback was HKD 981,000 [1] - The number of shares repurchased was 138,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Core Insights - The company will present preclinical data on its oral, potent pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC conference in Boston from October 22 to October 26, 2025 [1] - The abstract will be released on October 22, 2025, and the poster will be displayed on October 23, 2025, highlighting the drug's selectivity and efficacy [1] Company Overview - JAB-23E73 demonstrates exceptional antitumor activity across various cancer types with different KRAS mutations or amplifications [2] - The drug effectively induces tumor regression in KRAS-driven mouse tumor models without significant weight changes, indicating good tolerability and a wide therapeutic window [2] - JAB-23E73 has favorable pharmacokinetic characteristics for oral administration, with its tumor p-ERK inhibition regulated by plasma concentration [2] - Phase I clinical trials for JAB-23E73 targeting advanced solid tumors with KRAS mutations are currently underway in China and the United States [2]

Core Insights - The company will present preclinical data on its Pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC conference in Boston from October 22 to October 26, 2025 [1] - JAB-23E73 is characterized as a highly potent and orally bioavailable inhibitor with strong selectivity for KRAS, avoiding inhibition of HRAS and NRAS [1][2] Company Developments - JAB-23E73 has demonstrated exceptional antitumor activity across various cancer types with different KRAS driver mutations or amplifications [2] - In mouse tumor models driven by KRAS, JAB-23E73 effectively induces tumor regression without significant weight changes, indicating good tolerability and a wide therapeutic window [2] - The drug exhibits favorable pharmacokinetic properties for oral administration, with its effect on tumor p-ERK inhibition regulated by plasma concentration [2] - Phase I clinical trials for JAB-23E73 targeting advanced solid tumors with KRAS mutations are currently underway in China and the United States (NCT06959615, NCT06973564) [2]

Core Points - The company will present preclinical data on the oral, highly potent pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC meeting in Boston from October 22 to October 26, 2025 [1] - The abstract for JAB-23E73 will be released on October 22, 2025, and will also be published as free supplementary content in the journal Molecular Cancer Therapeutics [1] - The poster presentation for JAB-23E73 is scheduled for October 23, 2025 [1] Drug Characteristics - JAB-23E73 exhibits excellent antitumor activity across various cancer types with different KRAS driver mutations or amplifications [2] - In mouse tumor models driven by KRAS, JAB-23E73 effectively induces tumor regression without significant weight changes, indicating good tolerability and a wide therapeutic window [2] - The drug has favorable pharmacokinetic properties for oral administration and regulates the inhibition of p-ERK in tumors based on its plasma concentration [2] Clinical Trials - Phase I clinical trials for JAB-23E73 targeting advanced solid tumors with KRAS gene mutations are currently underway in China and the United States [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展。 本公司董事會（「董事會」）欣然宣佈，本公司於2025年10月22日至2025年10月26日在美國馬 薩諸塞州波士頓的海因斯會議中心舉行的2025年美國癌癥研究協會國際分子靶點與癌癥 治療學會議（「2025 AACR-NCI-EORTC大會」）上以摘要和海報的形式公佈標題為「口服可 吸收、強效的泛KRAS（開啟╱關閉）抑制劑JAB-23E73的臨床前研究」的Pan-KRAS抑制劑 JAB-23E73的臨床前數據。 JAB-23E73摘要（無海報）於美國東部時間2025年10月22日（星期三）下午12時通過會議應用 程序發佈，並且還將作為免費補充內容在AACR期刊《分子癌症治療學》上公佈。JAB- 23E73海報的展示時間是美國東部時間2025年10月23 ...

Group 1 - The company, 加科思-B (01167), announced a share buyback plan, spending HKD 992,000 to repurchase 138,000 shares [1]

Core Viewpoint - 加科思-B (01167) announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1 - The company will spend HKD 992,000 to repurchase 138,000 shares [1]

Core Viewpoint - The company, 加科思-B (01167.HK), announced a share buyback on October 23, 2023, spending HKD 992,000 to repurchase 138,000 shares [1] Group 1 - The total expenditure for the share buyback was HKD 992,000 [1] - The number of shares repurchased in this transaction was 138,000 [1]